Wedbush Lowers Voyager Therapeutics (NASDAQ:VYGR) Price Target to $8.00

Key Points

• Wedbush has lowered its price target for Voyager Therapeutics from $9.00 to $8.00, while maintaining an "outperform" rating, suggesting a potential upside of 138.81% from the last closing price.
• Despite the recent price target reduction, Voyager Therapeutics reported a quarterly earnings miss, with an EPS of ($0.57) against an expected ($0.48) and revenue of $5.20 million, which fell short of the $9.50 million forecast.
• Institutional investors own approximately 48.03% of Voyager Therapeutics’ stock, with several hedge funds acquiring new stakes during the second quarter.

Voyager Therapeutics (NASDAQ:VYGR - Free Report) had its target price decreased by Wedbush from $9.00 to $8.00 in a research report released on Thursday,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Voyager Therapeutics Stock Down 1.3%

Voyager Therapeutics stock traded down $0.04 during trading on Thursday, reaching $3.10. The stock had a trading volume of 544,256 shares, compared to its average volume of 519,452. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $8.27. The business has a 50 day moving average price of $3.23 and a 200 day moving average price of $3.62. The stock has a market cap of $171.90 million, a PE ratio of -1.69 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The company had revenue of $5.20 million for the quarter, compared to analysts' expectations of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. On average, equities analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth approximately $29,000. Tower Research Capital LLC TRC raised its holdings in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after buying an additional 3,077 shares during the period. CWM LLC increased its holdings in shares of Voyager Therapeutics by 856.3% in the 1st quarter. CWM LLC now owns 10,471 shares of the company's stock valued at $35,000 after purchasing an additional 9,376 shares during the period. Oxford Asset Management LLP acquired a new position in Voyager Therapeutics in the fourth quarter worth approximately $60,000. Finally, Bank of Montreal Can bought a new stake in Voyager Therapeutics during the second quarter worth approximately $36,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.